{"id":61122,"date":"2024-02-28T07:25:39","date_gmt":"2024-02-28T07:25:39","guid":{"rendered":"https:\/\/medsname.com\/affexor-xr\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"affexor-xr","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/affexor-xr\/","title":{"rendered":"Affexor XR"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Affexor XR?<\/h3>\n
\n

Affexor XR<\/strong> obsahuje venlafaxin ER (37,5 \/ 75 \/ 150 mg ER)<\/strong> od v\u00fdrobce certifikovan\u00e9ho WHO-GMP (Pfizer (India)) \u2014 SNRI<\/strong> s \u0161irokou d\u016fkazn\u00ed z\u00e1kladnou u depresivn\u00edch a \u00fazkostn\u00fdch poruch. Standardn\u00ed za\u010d\u00e1tek: 75 mg jednou denn\u011b<\/strong> s j\u00eddlem; titrujte na 150\u2013225 mg\/den pro plnou SNRI aktivitu (max. 375 mg u MDD, 225 mg u GAD\/soci\u00e1ln\u00ed \u00fazkosti\/paniky). N\u00e1stup \u00fa\u010dinku: 2\u20134 t\u00fddny. P\u0159i d\u00e1vk\u00e1ch pod 150 mg l\u00e9k p\u016fsob\u00ed p\u0159ev\u00e1\u017en\u011b jako SSRI; inhibice zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed noradrenalinu se objevuje p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch. D\u016fle\u017eit\u00e9<\/strong>: z\u00e1visl\u00e9 na d\u00e1vce vzestup krevn\u00edho tlaku<\/strong> (TK mus\u00ed b\u00fdt monitorov\u00e1n p\u0159i > 225 mg). M\u00e1 z\u00e1va\u017en\u00fd abstinen\u010dn\u00ed syndrom<\/strong> \u2014 povinn\u00e9 postupn\u00e9 vysazov\u00e1n\u00ed. P\u0159i p\u0159ed\u00e1vkov\u00e1n\u00ed je nebezpe\u010dn\u011bj\u0161\u00ed ne\u017e SSRI (kardiotoxicita, z\u00e1chvaty).<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n<\/div>\n

D\u016fle\u017eit\u00e9 \u2014 nejedn\u00e1 se o l\u00e9k na situa\u010dn\u00ed \u00fazkost.<\/strong> Affexor XR je inhibitor zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed serotoninu a noradrenalinu (SNRI)<\/strong>, p\u0159edepisov\u00e1n a titrov\u00e1n po t\u00fddny pro z\u00e1va\u017en\u00e1 depresivn\u00ed porucha (MDD), generalizovan\u00e1 \u00fazkostn\u00e1 porucha (GAD), soci\u00e1ln\u00ed \u00fazkostn\u00e1 porucha a panick\u00e1 porucha<\/strong>. Nen\u00ed ne<\/strong> spr\u00e1vn\u00fdm l\u00e9kem pro akutn\u00ed, v\u00fdkonov\u011b souvisej\u00edc\u00ed \u00fazkost (l\u00e9t\u00e1n\u00ed, ve\u0159ejn\u00e9 vystupov\u00e1n\u00ed, zkou\u0161ky) \u2014 pro tyto p\u0159\u00edpady jsou klinicky vhodn\u011bj\u0161\u00ed betablok\u00e1tory (propranolol), benzodiazepiny nebo hydroxyzin. Pokud nem\u00e1te diagnostikovanou poruchu n\u00e1lady, \u00fazkostnou nebo psychiatrickou poruchu, neza\u010d\u00ednejte s u\u017e\u00edv\u00e1n\u00edm tohoto l\u00e9ku.<\/div>\n
FDA \u010dern\u00e9 varov\u00e1n\u00ed \u2014 sebevra\u017eednost.<\/strong> V\u0161echna antidepresiva nesou \u010dern\u00e9 varov\u00e1n\u00ed FDA pro zv\u00fd\u0161en\u00e9 riziko sebevra\u017eedn\u00e9ho my\u0161len\u00ed a chov\u00e1n\u00ed u d\u011bt\u00ed, dosp\u00edvaj\u00edc\u00edch a mlad\u00fdch dosp\u011bl\u00fdch do 25 let, zejm\u00e9na b\u011bhem prvn\u00edch t\u00fddn\u016f l\u00e9\u010dby nebo po zm\u011bn\u00e1ch d\u00e1vkov\u00e1n\u00ed. \u010clenov\u00e9 rodiny a p\u0159edepisuj\u00edc\u00ed l\u00e9ka\u0159i by m\u011bli pe\u010dliv\u011b sledovat zhor\u0161en\u00ed n\u00e1lady, agitovanost nebo sebevra\u017eedn\u00e9 my\u0161lenky v t\u00e9to v\u011bkov\u00e9 skupin\u011b.<\/div>\n

Co je Affexor XR?<\/h2>\n

Affexor XR je peror\u00e1ln\u00ed tableta\/tobolka s prodlou\u017een\u00fdm uvol\u0148ov\u00e1n\u00edm venlafaxinu (37,5 \/ 75 \/ 150 mg ER)<\/strong> vyr\u00e1b\u011bn\u00fd spole\u010dnost\u00ed Pfizer (Indie) v r\u00e1mci certifikace WHO-GMP. Venlafaxin (americk\u00e1 zna\u010dka Effexor XR<\/strong>) je prototyp inhibitor zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed serotoninu a noradrenalinu (SNRI)<\/strong>. Blokuje jak serotoninov\u00fd transport\u00e9r (SERT) p\u0159i ni\u017e\u0161\u00edch d\u00e1vk\u00e1ch, tak noradrenalinov\u00fd transport\u00e9r (NET) p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch, co\u017e vede k d\u00e1vkov\u011b z\u00e1visl\u00e9mu posunu od SSRI-like k SNRI-like farmakologii.<\/p>\n

Je l\u00e9kem prvn\u00ed volby v doporu\u010den\u00edch NICE a APA pro l\u00e9\u010dbu z\u00e1va\u017en\u00e9 deprese a pat\u0159\u00ed mezi nejl\u00e9pe prok\u00e1zan\u00e1 antidepresiva pro generalizovanou \u00fazkostnou poruchu.<\/p>\n

Schv\u00e1len\u00e9 indikace<\/h2>\n
    \n
  • Hlavn\u00ed depresivn\u00ed porucha (MDD)<\/strong> \u2014 v\u010detn\u011b l\u00e9\u010debn\u011b rezistentn\u00ed deprese p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch<\/li>\n
  • Generalizovan\u00e1 \u00fazkostn\u00e1 porucha (GAD)<\/strong><\/li>\n
  • Soci\u00e1ln\u00ed \u00fazkostn\u00e1 porucha (chronick\u00e1\/generalizovan\u00e1)<\/strong><\/li>\n
  • panick\u00e1 porucha<\/strong> \u2014 s agorafobi\u00ed i bez n\u00ed<\/li>\n
  • Mimo schv\u00e1len\u00e9 indikace: diabetick\u00e1 neuropatie, chronick\u00fd \u00fanavov\u00fd syndrom, fibromyalgie, vazomotorick\u00e9 p\u0159\u00edznaky menopauzy<\/li>\n<\/ul>\n

    D\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n
    Indikace<\/th>\nStart<\/th>\nTypick\u00e9 \u00fa\u010dinn\u00e9 rozmez\u00ed<\/th>\nMaxim\u00e1ln\u011b<\/th>\nPozn\u00e1mky<\/th>\n<\/tr>\n<\/thead>\n
    MDD<\/td>\n75 mg\/den s j\u00eddlem<\/td>\n150\u2013225 mg\/den<\/td>\n375 mg\/den<\/td>\nZvy\u0161ovat o 75 mg ka\u017ed\u00e9 2 t\u00fddny<\/td>\n<\/tr>\n
    GAD, soci\u00e1ln\u00ed \u00fazkost, panika<\/td>\n37,5\u201375 mg\/den<\/td>\n75\u2013225 mg\/den<\/td>\n225 mg\/den<\/td>\nPomalej\u0161\u00ed titrace u panick\u00e9 poruchy, aby se p\u0159ede\u0161lo \u010dasn\u00e9 agitaci<\/td>\n<\/tr>\n
    Star\u0161\u00ed pacienti\/jatern\u00ed\/ren\u00e1ln\u00ed posti\u017een\u00ed<\/td>\n37,5 mg\/den<\/td>\nA\u017e 75\u2013150 mg s opatrnost\u00ed<\/td>\n\u2014<\/td>\nSn\u00ed\u017eit o 25\u201350 % p\u0159i st\u0159edn\u00edm jatern\u00edm posti\u017een\u00ed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Mechanismus podle d\u00e1vky<\/h2>\n

    Farmakologick\u00e9 \u00fa\u010dinky se m\u011bn\u00ed s rostouc\u00ed d\u00e1vkou<\/h2>\n\n\n\n\n\n\n\n\n
    Denn\u00ed d\u00e1vka<\/th>\nFarmakologie<\/th>\nKlinick\u00fd v\u00fdznam<\/th>\n<\/tr>\n<\/thead>\n
    37,5\u201375 mg<\/td>\nP\u0159ev\u00e1\u017en\u011b serotoninergn\u00ed (podobn\u00e9 SSRI)<\/td>\nVhodn\u00e9 jako po\u010d\u00e1te\u010dn\u00ed\/subterapeutick\u00e1 d\u00e1vka pro lep\u0161\u00ed sn\u00e1\u0161enlivost<\/td>\n<\/tr>\n
    75\u2013150 mg<\/td>\nP\u0159ev\u00e1\u017en\u011b serotoninergn\u00ed s rozv\u00edjej\u00edc\u00ed se noradrenergn\u00ed aktivitou<\/td>\nSpodn\u00ed hranice \u00fa\u010dinn\u00e9ho antidepresivn\u00edho rozmez\u00ed<\/td>\n<\/tr>\n
    150\u2013225 mg<\/td>\nKombinovan\u00e1 inhibice SERT + NET (prav\u00e9 SNRI)<\/td>\nStandardn\u00ed \u00fa\u010dinn\u00e1 d\u00e1vka pro v\u011bt\u0161inu dosp\u011bl\u00fdch; pln\u00fd p\u0159\u00ednos SNRI<\/td>\n<\/tr>\n
    225\u2013375 mg (pouze u MDD)<\/td>\nSiln\u00e1 inhibice SERT + NET<\/td>\nPou\u017e\u00edv\u00e1 se u l\u00e9\u010debn\u011b rezistentn\u00ed deprese; vy\u017eaduje se monitorov\u00e1n\u00ed TK a srde\u010dn\u00ed \u010dinnosti<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Vedlej\u0161\u00ed \u00fa\u010dinky<\/h2>\n

    B\u011b\u017en\u00e9, p\u0159etrv\u00e1vaj\u00edc\u00ed a vz\u00e1cn\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Frekvence<\/th>\n\u00da\u010dinek<\/th>\nPozn\u00e1mky \/ management<\/th>\n<\/tr>\n<\/thead>\n
    B\u011b\u017en\u00e9<\/td>\nNevolnost (z\u00e1visl\u00e1 na d\u00e1vce)<\/td>\nU\u017e\u00edvat s j\u00eddlem; obvykle ustoup\u00ed b\u011bhem 1\u20132 t\u00fddn\u016f<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nBolest hlavy, z\u00e1vrat\u011b<\/td>\nP\u0159echodn\u00fd stav; dostate\u010dn\u00e1 hydratace<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nNespavost nebo ospalost<\/td>\n\u010casto d\u00e1vkovat r\u00e1no, pokud m\u00e1 aktiva\u010dn\u00ed \u00fa\u010dinek<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSucho v \u00fastech, z\u00e1cpa, pocen\u00ed<\/td>\nPocen\u00ed m\u016f\u017ee p\u0159etrv\u00e1vat; m\u016f\u017ee b\u00fdt v\u00fdrazn\u00e9<\/td>\n<\/tr>\n
    B\u011b\u017en\u00e9<\/td>\nSexu\u00e1ln\u00ed dysfunkce<\/td>\nPodobn\u00e1 prevalence jako u SSRI<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nZv\u00fd\u0161en\u00fd krevn\u00ed tlak (z\u00e1visl\u00fd na d\u00e1vce)<\/td>\nM\u011b\u0159it TK na za\u010d\u00e1tku a pravideln\u011b; v\u00fdrazn\u00fd vzestup nad 225 mg\/den u 5\u201310 % pacient\u016f \u2014 m\u016f\u017ee b\u00fdt nutn\u00e1 redukce d\u00e1vky nebo zm\u011bna l\u00e9\u010dby<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nZv\u00fd\u0161en\u00e1 tepov\u00e1 frekvence, palpitace<\/td>\nOpatrnost u pacient\u016f se srde\u010dn\u00edm onemocn\u011bn\u00edm<\/td>\n<\/tr>\n
    M\u00e9n\u011b \u010dast\u00e9<\/td>\nZm\u011bny hmotnosti (m\u00edrn\u00e9)<\/td>\nMen\u0161\u00ed p\u0159\u00edr\u016fstek hmotnosti ne\u017e u paroxetinu nebo mirtazapinu<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nHyponatr\u00e9mie (SIADH)<\/td>\nNejvy\u0161\u0161\u00ed riziko maj\u00ed star\u0161\u00ed dosp\u011bl\u00ed<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nRiziko krv\u00e1cen\u00ed<\/td>\nOpatrnost p\u0159i u\u017e\u00edv\u00e1n\u00ed NSAID, antikoagulanci\u00ed<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nSerotoninov\u00fd syndrom<\/td>\nInterakce<\/td>\n<\/tr>\n
    Vz\u00e1cn\u00e9<\/td>\nMydri\u00e1za \/ akutn\u00ed glaukom s uzav\u0159en\u00fdm \u00fahlem<\/td>\nOpatrnost u \u00fazk\u00e9ho \u00fahlu glaukomu<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    Syndrom z vysazen\u00ed<\/h2>\n

    Venlafaxin m\u00e1 kr\u00e1tk\u00fd polo\u010das<\/strong> (mate\u0159sk\u00e1 l\u00e1tka ~5 h; aktivn\u00ed metabolit desvenlafaxin ~11 h). P\u0159\u00edznaky vysazen\u00ed jsou z\u00e1va\u017en\u00e9 a rychl\u00e9<\/strong>, druh\u00e9 pouze po paroxetinu: mozkov\u00e9 v\u00fdboje, z\u00e1vrat\u011b, nevolnost, pocen\u00ed, podr\u00e1\u017ed\u011bnost, nespavost, \u017eiv\u00e9 sny, ch\u0159ipkov\u00e9 bolesti. \u010casto se objevuj\u00ed do 24\u201348 hodin po vynech\u00e1n\u00ed d\u00e1vky.<\/p>\n

    Povinn\u00e9 pomal\u00e9 vysazov\u00e1n\u00ed<\/strong>: sni\u017eujte o 75 mg ka\u017ed\u00e9 2\u20134 t\u00fddny; pod 75 mg pou\u017eijte nejmen\u0161\u00ed dostupnou kapsli a zva\u017ete obdenn\u00ed nebo hyperbolick\u00e9 vysazov\u00e1n\u00ed. Nikdy nep\u0159est\u00e1vejte n\u00e1hle. Pacienti na dlouhodob\u00e9m venlafaxinu \u010dasto tr\u00e1v\u00ed m\u011bs\u00edce vysazov\u00e1n\u00edm \u2014 to je norm\u00e1ln\u00ed.<\/p>\n

    Interakce s l\u00e9\u010divy<\/h2>\n

    Absolutn\u00ed kontraindikace<\/strong>: MAOI, linezolid, methylenov\u00e1 mod\u0159. 14denn\u00ed vyplaven\u00ed.<\/p>\n

    Serotonergn\u00ed interakce<\/strong>: triptany, tramadol, petidin, dextromethorfan, t\u0159ezalka te\u010dkovan\u00e1, lithium \u2014 riziko serotoninov\u00e9ho syndromu.<\/p>\n

    Substr\u00e1t CYP2D6<\/strong>: hladiny stoupaj\u00ed se siln\u00fdmi inhibitory CYP2D6 (paroxetin, fluoxetin, bupropion, chinidin). Zva\u017ete sn\u00ed\u017een\u00ed d\u00e1vky.<\/p>\n

    Riziko krv\u00e1cen\u00ed<\/strong>: NSAID, aspirin, warfarin, DOAC.<\/p>\n

    Srde\u010dn\u00ed a p\u0159ed\u00e1vkovac\u00ed aspekty<\/h2>\n

    Venlafaxine je nebezpe\u010dn\u011bj\u0161\u00ed p\u0159i p\u0159ed\u00e1vkov\u00e1n\u00ed ne\u017e SSRI<\/strong>: byly hl\u00e1\u0161eny poruchy srde\u010dn\u00edho veden\u00ed, prodlou\u017een\u00ed QT intervalu, z\u00e1chvaty a serotoninov\u00fd syndrom. P\u0159edepisujte pouze kr\u00e1tkodob\u00e9 z\u00e1soby pacient\u016fm s akutn\u00edm rizikem sebevra\u017edy. V\u00fdznamn\u00e9 p\u0159edchoz\u00ed srde\u010dn\u00ed onemocn\u011bn\u00ed, ned\u00e1vn\u00fd infarkt myokardu nebo nekontrolovan\u00e1 hypertenze jsou relativn\u00ed kontraindikace.<\/p>\n

    \u010casto kladen\u00e9 dotazy<\/h2>\n

    Jak dlouho trv\u00e1, ne\u017e Affexor XR za\u010dne \u00fa\u010dinkovat?<\/h3>\n

    P\u0159\u00edznaky \u00fazkosti se \u010dasto zlep\u0161\u00ed za 2\u20133 t\u00fddny; \u00fa\u010dinek na n\u00e1ladu u MDD se obvykle objev\u00ed za 4\u20136 t\u00fddn\u016f. Pacienti na subterapeutick\u00fdch d\u00e1vk\u00e1ch (< 150 mg) mohou pot\u0159ebovat zv\u00fd\u0161en\u00ed d\u00e1vky p\u0159ed dosa\u017een\u00edm pln\u00e9ho \u00fa\u010dinku.<\/p>\n

    Pro\u010d je d\u00e1vkov\u00e1n\u00ed u venlafaxinu tak d\u016fle\u017eit\u00e9?<\/h3>\n

    P\u0159i d\u00e1vk\u00e1ch pod 150 mg\/den p\u016fsob\u00ed venlafaxin p\u0159ev\u00e1\u017en\u011b jako SSRI \u2014 inhibice zp\u011btn\u00e9ho vychyt\u00e1v\u00e1n\u00ed noradrenalinu se objevuje a\u017e p\u0159i vy\u0161\u0161\u00edch d\u00e1vk\u00e1ch. Pacienti, kte\u0159\u00ed nereaguj\u00ed na 75 mg, \u010dasto reaguj\u00ed po titraci na 150 mg nebo v\u00edce.<\/p>\n

    M\u016f\u017ee Affexor XR zv\u00fd\u0161it m\u016fj krevn\u00ed tlak?<\/h3>\n

    Mo\u017en\u00e1 \u2014 venlafaxin zp\u016fsobuje d\u00e1vkov\u011b z\u00e1visl\u00e9 zv\u00fd\u0161en\u00ed krevn\u00edho tlaku. P\u0159i d\u00e1vk\u00e1ch pod 150 mg je \u00fa\u010dinek mal\u00fd; nad 225 mg zaznamen\u00e1 klinicky v\u00fdznamn\u00e9 zv\u00fd\u0161en\u00ed 5\u201310 % pacient\u016f. Krevn\u00ed tlak by m\u011bl b\u00fdt monitorov\u00e1n na za\u010d\u00e1tku a po zv\u00fd\u0161en\u00ed d\u00e1vky.<\/p>\n

    Mohu Affexor XR n\u00e1hle vysadit?<\/h3>\n

    Ne \u2014 venlafaxin m\u00e1 jeden z nejhor\u0161\u00edch abstinen\u010dn\u00edch syndrom\u016f ve t\u0159\u00edd\u011b antidepresiv (mozkov\u00e9 v\u00fdboje, z\u00e1vrat\u011b, nevolnost, pocen\u00ed). Je nutn\u00e9 postupn\u00e9 vysazov\u00e1n\u00ed, \u010dasto po m\u011bs\u00edce u dlouhodob\u00fdch u\u017eivatel\u016f.<\/p>\n

    Je Affexor XR bezpe\u010dn\u00fd v t\u011bhotenstv\u00ed?<\/h3>\n

    Omezen\u00e9 \u00fadaje \u2014 nen\u00ed antidepresivem prvn\u00ed volby v t\u011bhotenstv\u00ed. Preferuje se sertralin. Expozice v pozdn\u00edm t\u0159et\u00edm trimestru nese mal\u00e9 riziko neonat\u00e1ln\u00edho adapta\u010dn\u00edho syndromu a perzistuj\u00edc\u00ed plicn\u00ed hypertenze novorozence.<\/p>\n

    Zp\u016fsobuje Affexor XR p\u0159ib\u00fdv\u00e1n\u00ed na v\u00e1ze?<\/h3>\n

    M\u00e9n\u011b ne\u017e paroxetin nebo mirtazapin. N\u011bkte\u0159\u00ed pacienti zaznamenaj\u00ed m\u00edrn\u00e9 zm\u011bny hmotnosti; jin\u00ed hubnou kv\u016fli po\u010d\u00e1te\u010dn\u00edm gastrointestin\u00e1ln\u00edm ne\u017e\u00e1douc\u00edm \u00fa\u010dink\u016fm. Men\u0161\u00ed metabolick\u00e1 z\u00e1t\u011b\u017e ne\u017e u antipsychotik.<\/p>\n

    Mohu p\u00edt alkohol p\u0159i u\u017e\u00edv\u00e1n\u00ed Affexor XR?<\/h3>\n

    Lehk\u00e1, p\u0159\u00edle\u017eitostn\u00e1 konzumace alkoholu je obecn\u011b tolerov\u00e1na. Nadm\u011brn\u00e9 pit\u00ed alkoholu zhor\u0161uje depresi\/\u00fazkost, zvy\u0161uje sedaci a m\u016f\u017ee v\u00e9st k disinhibovan\u00e9mu chov\u00e1n\u00ed.<\/p>\n

    Co se stane, kdy\u017e vynech\u00e1m d\u00e1vku?<\/h3>\n

    Vezm\u011bte l\u00e9k, jakmile si vzpomenete, pokud nen\u00ed bl\u00edzko dal\u0161\u00ed d\u00e1vka. Abstinen\u010dn\u00ed p\u0159\u00edznaky se mohou objevit ji\u017e 24\u201348 hodin po vynech\u00e1n\u00ed d\u00e1vky \u2013 nevynech\u00e1vejte v\u00edce d\u00e1vek.<\/p>\n

    Jak se Affexor XR li\u0161\u00ed od duloxetinu nebo desvenlafaxinu?<\/h3>\n

    V\u0161echny jsou SNRI. Duloxetin m\u00e1 odli\u0161n\u00fd vazebn\u00fd profil (v\u00edce SNRI i p\u0159i ni\u017e\u0161\u00edch d\u00e1vk\u00e1ch, hepat\u00e1ln\u00ed rizika) a je schv\u00e1len tak\u00e9 pro diabetickou neuropatii a fibromyalgii. Desvenlafaxin je aktivn\u00ed metabolit venlafaxinu \u2013 obch\u00e1z\u00ed metabolismus CYP2D6, m\u00e1 p\u0159edv\u00eddateln\u011bj\u0161\u00ed plazmatick\u00e9 hladiny.<\/p>\n

    Jak by m\u011bl b\u00fdt Affexor XR skladov\u00e1n?<\/h3>\n

    Skladujte p\u0159i teplot\u011b 15\u201330 \u00b0C v p\u016fvodn\u00edm blistrov\u00e9m obalu, mimo vlhkost a p\u0159\u00edm\u00e9 slune\u010dn\u00ed sv\u011btlo. Uchov\u00e1vejte mimo dosah d\u011bt\u00ed \u2013 p\u0159ed\u00e1vkov\u00e1n\u00ed venlafaxinem je medic\u00ednsky z\u00e1va\u017en\u00e9.<\/p>\n

    Zdravotn\u00ed upozorn\u011bn\u00ed:<\/strong> Informace na t\u00e9to str\u00e1nce jsou ur\u010deny dosp\u011bl\u00fdm u\u017e\u00edvaj\u00edc\u00edm p\u0159edepsan\u00e9 psychiatrick\u00e9 l\u00e9ky a nenahrazuj\u00ed individu\u00e1ln\u00ed l\u00e9ka\u0159skou p\u00e9\u010di. Antidepresiva, antipsychotika a p\u0159\u00edbuzn\u00e9 l\u00e9ky mohou interagovat s jin\u00fdmi l\u00e9ky, alkoholem a st\u00e1vaj\u00edc\u00edmi zdravotn\u00edmi stavy. Jak\u00e9koli nov\u00e9 l\u00e9ky, zm\u011bnu d\u00e1vkov\u00e1n\u00ed nebo pl\u00e1novan\u00e9 vysazen\u00ed konzultujte s kvalifikovan\u00fdm l\u00e9ka\u0159em. Pokud se u v\u00e1s objev\u00ed sebevra\u017eedn\u00e9 my\u0161lenky, m\u00e1nie, t\u011b\u017ek\u00e1 akathisie, p\u0159\u00edznaky serotoninov\u00e9ho syndromu (vysok\u00e1 hore\u010dka, zmatenost, svalov\u00e1 ztuhlost, zrychlen\u00fd srde\u010dn\u00ed tep) nebo neuroleptick\u00fd malign\u00ed syndrom, vyhledejte okam\u017eit\u011b l\u00e9ka\u0159skou pomoc.<\/div>\n

    <\/p>\n

    Souvisej\u00edc\u00ed alternativy<\/h3>\n

    Dal\u0161\u00ed produkty v Chronick\u00e1 onemocn\u011bn\u00ed<\/strong> kter\u00e9 z\u00e1kazn\u00edci tak\u00e9 prohl\u00ed\u017eej\u00ed:<\/p>\n